Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Kubicki, Tadeusz
25  Ergebnisse:
Personensuche X
?
1

Final analysis of a phase II trial of daratumumab, carfilzo..:

Derman, Benjamin A. ; Cooperrider, Jennifer ; Rosenblatt, Jacalyn...
Blood Cancer Journal.  14 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
2

G6PD deficiency—does it alter the course of COVID-19 infect..:

Au, Tsz Yuen ; Wiśniewski, Oskar Wojciech ; Benjamin, Shamiram...
Annals of Hematology.  102 (2023)  7 - p. 1629-1636 , 2023
Link: https://doi.org/10.1007/..
 
?
3

P-397 Polyclonal immunoglobulin recovery in myeloma patient..:

Kubicki, Tadeusz ; Dytfeld, Dominik ; Wrobel, Tomasz...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S259-S260 , 2023
Link: https://doi.org/10.1016/..
 
?
4

HRAS mutation positive multiple myeloma in the type 2 CALR ..:

Lewandowski, Krzysztof ; Kopydłowska, Agata ; Kanduła, Zuzanna...
Journal of Cellular and Molecular Medicine.  27 (2023)  2 - p. 299-303 , 2023
Link: https://doi.org/10.1111/..
 
?
5

Polyclonal immunoglobulin recovery in patients with newly d..:

Kubicki, Tadeusz ; Dytfeld, Dominik ; Wróbel, Tomasz...
British Journal of Haematology.  203 (2023)  5 - p. 792-802 , 2023
Link: https://doi.org/10.1111/..
 
?
6

OAB-010: Atlas: a phase 3 randomized trial of carfilzomib, ..:

Jakubowiak, Andrzej ; Wrobel, Tomasz ; Jamroziak, Krzysztof...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S6 , 2022
Link: https://doi.org/10.1016/..
 
?
7

Measurable residual disease assessed by mass spectrometry i..:

Derman, Benjamin A. ; Stefka, Andrew T. ; Jiang, Ken...
Blood Cancer Journal.  11 (2021)  2 - p. , 2021
Link: https://doi.org/10.1038/..
 
?
8

Comparative proteomic profiling of refractory/relapsed mult..:

Dytfeld, Dominik ; Luczak, Magdalena ; Wrobel, Tomasz...
Oncotarget.  7 (2016)  35 - p. 56726-56736 , 2016
Link: https://doi.org/10.18632..
 
?
9

Carfilzomib, lenalidomide, and dexamethasone or lenalidomid..:

Dytfeld, Dominik ; Wróbel, Tomasz ; Jamroziak, Krzysztof...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337122/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
10

G6PD deficiency—does it alter the course of COVID-19 infect..:

Au, Tsz Yuen ; Wiśniewski, Oskar Wojciech ; Benjamin, Shamiram...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006571/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
11

Bortezomib- and carfilzomib-resistant myeloma cells show in..:

Kubicki, Tadeusz ; Bednarek, Kinga ; Kostrzewska-Poczekaj, Magdalena...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360248/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
12

Measurable residual disease assessed by mass spectrometry i..:

Derman, Benjamin A ; Stefka, Andrew T ; Jiang, Ken...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873068/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
13

Carfilzomib, lenalidomide, and dexamethasone plus transplan..:

Jasielec, Jagoda K ; Kubicki, Tadeusz ; Raje, Noopur...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714092/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
14

High efficacy and safety of VTD as an induction protocol in..:

Hus, Iwona ; Mańko, Joanna ; Jawniak, Dariusz...
Oncology Letters, T. 18, nr 6, s. 5811-5820.  , 2019
Link: https://ruj.uj.edu.pl/xm..
 
?
15

HRAS mutation positive multiple myeloma in the type 2 CALR ..:

Krzysztof, Lewandowski ; Agata, Kopydłowska ; Zuzanna, Kanduła...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843526/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
1-15